Who are Aspirin + Clopidogrel + Rivaroxaban's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clopidogrel + ASA + Bivalirudin, Acetylsalicylic Acid + clopidogrel + acenocoumarol, Ticagrelor + ASA + Bivalirudin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aspirin-clopidogrel-rivaroxaban.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Aspirin + Clopidogrel + Rivaroxaban — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aspirin + Clopidogrel + Rivaroxaban (Aspirin + Clopidogrel + Rivaroxaban) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent + Anticoagulant combination. Area: Cardiovascular.

marketed Antiplatelet agent + Anticoagulant combination Platelet cyclooxygenase, P2Y12 receptor, Factor Xa Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Aspirin + Clopidogrel + Rivaroxaban (Aspirin + Clopidogrel + Rivaroxaban) — China National Center for Cardiovascular Diseases. This triple anticoagulant/antiplatelet combination inhibits blood clotting through multiple pathways: aspirin and clopidogrel block platelet aggregation, while rivaroxaban inhibits Factor Xa in the coagulation cascade.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Aspirin + Clopidogrel + Rivaroxaban TARGET	Aspirin + Clopidogrel + Rivaroxaban	China National Center for Cardiovascular Diseases	marketed	Antiplatelet agent + Anticoagulant combination	Platelet cyclooxygenase, P2Y12 receptor, Factor Xa
Clopidogrel + ASA + Bivalirudin	Clopidogrel + ASA + Bivalirudin	Juan J Badimon	marketed	Antiplatelet agent + Anticoagulant combination	P2Y12 receptor, cyclooxygenase, thrombin
Acetylsalicylic Acid + clopidogrel + acenocoumarol	Acetylsalicylic Acid + clopidogrel + acenocoumarol	Hospital Universitari Vall d'Hebron Research Institute	marketed	Antiplatelet agent + Anticoagulant combination	Platelet cyclooxygenase (COX), P2Y12 receptor, Vitamin K-dependent clotting factors
Ticagrelor + ASA + Bivalirudin	Ticagrelor + ASA + Bivalirudin	Juan J Badimon	marketed	Antiplatelet agent + anticoagulant combination	P2Y12 receptor, COX-1, thrombin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent + Anticoagulant combination class)

China National Center for Cardiovascular Diseases · 1 drug in this class
Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
Juan J Badimon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aspirin + Clopidogrel + Rivaroxaban — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-clopidogrel-rivaroxaban. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab